CO5700792A2 - Un agente preventivo para la vasculitis - Google Patents
Un agente preventivo para la vasculitisInfo
- Publication number
- CO5700792A2 CO5700792A2 CO06069184A CO06069184A CO5700792A2 CO 5700792 A2 CO5700792 A2 CO 5700792A2 CO 06069184 A CO06069184 A CO 06069184A CO 06069184 A CO06069184 A CO 06069184A CO 5700792 A2 CO5700792 A2 CO 5700792A2
- Authority
- CO
- Colombia
- Prior art keywords
- preventive
- vasculitis
- receptor
- therapeutic agent
- antibody against
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
1.- Un agente preventivo y/o terapéutico para la vasculitis, comprendiendo dicho agente un antagonista de inteneuquina 6 (IL-6) como componente activo.2.- Un agente preventivo y/o terapéutico para la vasculitis que posee resistencia a esteroides y/o inmunosupresores, comprendiendo dicho agente un antagonista de interleuquina 6 (IL-6) como componente activo.3.- El agente preventivo y/o terapéutico de acuerdo con la reivindicación 1 o 2 en el cual dicha vasculitis es la poliarteritis nudosa.4.- El agente preventivo y/o terapéutico de acuerdo con la reivindicación 1 o 2 en el cual la vasculitis es el síndrome de aortitis.5.- El agente preventivo y/o terapéutico de acuerdo con la reivindicación 1 o 2 en el cual la vasculitis es la vasculitis asociada con anormalidades inmunológicas.6.- El agente preventivo y/o terapéutico de acuerdo con cualquiera de las reivindicaciones 1 a 5 en el cual dicho antagonista de IL-6 es un anticuerpo contra el receptor de IL-6.7.- El agente preventivo y/o terapéutico de acuerdo con la reivindicación 6 en el cual dicho anticuerpo contra el receptor de IL-6 es un anticuerpo monoclonal contra el receptor de IL-6.8.- El agente preventivo y/o terapéutico de acuerdo con la reivindicación 6 en el cual dicho anticuerpo contra el receptor de IL-6 es un anticuerpo monoclonal contra el receptor humano de IL-6.9.- El agente preventivo y/o terapéutico de acuerdo con la reivindicación 6 en el cual dicho anticuerpo contra el receptor de IL-6 es un anticuerpo monoclonal contra el receptor de IL-6 de ratón.10.- El agente preventivo y/o terapéutico de acuerdo con cualquiera de las reivindicaciones 6 a 9 en el cual dicho anticuerpo contra el receptor de IL-6 es un anticuerpo recombinante.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003423517 | 2003-12-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5700792A2 true CO5700792A2 (es) | 2006-11-30 |
Family
ID=34708761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO06069184A CO5700792A2 (es) | 2003-12-19 | 2006-07-14 | Un agente preventivo para la vasculitis |
Country Status (22)
Country | Link |
---|---|
US (1) | US20140079695A1 (es) |
EP (1) | EP1707215B1 (es) |
JP (1) | JP4785534B2 (es) |
KR (1) | KR101218532B1 (es) |
CN (1) | CN1893979B (es) |
AR (1) | AR048210A1 (es) |
AT (1) | ATE549034T1 (es) |
AU (1) | AU2004305379B2 (es) |
BR (1) | BRPI0417072B8 (es) |
CA (1) | CA2549467C (es) |
CO (1) | CO5700792A2 (es) |
DK (1) | DK1707215T3 (es) |
ES (1) | ES2382809T3 (es) |
HK (1) | HK1095751A1 (es) |
IL (1) | IL176122A (es) |
MY (1) | MY142986A (es) |
NO (1) | NO20062718L (es) |
NZ (1) | NZ547645A (es) |
RU (1) | RU2379054C2 (es) |
TW (1) | TWI351967B (es) |
WO (1) | WO2005061000A1 (es) |
ZA (1) | ZA200604655B (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE547119T1 (de) | 1997-03-21 | 2012-03-15 | Chugai Pharmaceutical Co Ltd | Präventives oder therapeutisches mittel mit einem il-6-antagonisten als wirkstoff für durch sensibilisierte t-zellen vermittelte erkrankungen |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
RU2446826C2 (ru) | 2005-10-14 | 2012-04-10 | Фукуока Юниверсити | Агенты для подавления повреждения трансплантированных островков после трансплантации островков |
AR058135A1 (es) * | 2005-10-21 | 2008-01-23 | Chugai Pharmaceutical Co Ltd | Agentes para el tratamiento de cardiopatias |
AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
JP5033643B2 (ja) | 2006-01-27 | 2012-09-26 | 学校法人慶應義塾 | 脈絡膜血管新生を伴う疾患の治療剤 |
DK2009101T3 (en) | 2006-03-31 | 2018-01-15 | Chugai Pharmaceutical Co Ltd | Antibody modification method for purification of a bispecific antibody |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
CA2648644C (en) | 2006-04-07 | 2016-01-05 | Osaka University | Muscle regeneration promoter |
JP2010095445A (ja) * | 2006-12-27 | 2010-04-30 | Tokyo Medical & Dental Univ | Il−6アンタゴニストを有効成分とする炎症性筋疾患治療剤 |
RU2450829C2 (ru) | 2007-01-23 | 2012-05-20 | Синсу Юниверсити | Ингибитор хронического отторжения |
MY163473A (en) | 2007-09-26 | 2017-09-15 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region |
SI2202245T1 (sl) | 2007-09-26 | 2016-10-28 | Chugai Seiyaku Kabushiki Kaisha | Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR |
DK2236604T3 (en) | 2007-12-05 | 2016-10-03 | Chugai Pharmaceutical Co Ltd | The anti-NR10 antibody and use thereof |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
CN107488228A (zh) | 2008-04-11 | 2017-12-19 | 中外制药株式会社 | 与多个分子的抗原反复结合的抗原结合分子 |
CN102256623A (zh) | 2008-06-05 | 2011-11-23 | 独立行政法人国立癌症研究中心 | 神经浸润抑制剂 |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
JP5787446B2 (ja) | 2009-03-19 | 2015-09-30 | 中外製薬株式会社 | 抗体定常領域改変体 |
CN102459344A (zh) | 2009-05-15 | 2012-05-16 | 中外制药株式会社 | 抗axl抗体 |
US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
BR122022001178B1 (pt) | 2009-10-26 | 2022-10-04 | F. Hoffmann-La Roche Ag | Método para a produção de uma imunoglobulina glicosilada e seu uso |
EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
PL2578231T3 (pl) | 2010-05-28 | 2023-01-16 | Chugai Seiyaku Kabushiki Kaisha | Środek wzmacniający przeciwnowotworową odpowiedź limfocytów t |
WO2012064627A2 (en) | 2010-11-08 | 2012-05-18 | Genentech, Inc. | Subcutaneously administered anti-il-6 receptor antibody |
RU2658504C9 (ru) | 2010-11-30 | 2018-08-21 | Чугаи Сейяку Кабусики Кайся | Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул |
ES2690557T3 (es) | 2011-06-02 | 2018-11-21 | University Of Louisville Research Foundation, Inc. | Nanopartículas conjugadas a un agente antinucleolina |
JP6442404B2 (ja) | 2013-06-11 | 2018-12-19 | 国立研究開発法人国立精神・神経医療研究センター | 再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法 |
MX363403B (es) | 2013-07-04 | 2019-03-22 | Hoffmann La Roche | Inmumoensayo con interferencia suprimida para la deteccion de anticuerpos anti-farmacos en muestras de suero. |
BR112016006197B1 (pt) | 2013-09-27 | 2023-04-11 | Chugai Seiyaku Kabushiki Kaisha | Método para produzir um anticorpo biespecífico de polipeptídeos |
KR20180095740A (ko) | 2015-02-27 | 2018-08-27 | 추가이 세이야쿠 가부시키가이샤 | Il-6 관련 질환 치료용 조성물 |
WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
WO2016179394A1 (en) | 2015-05-05 | 2016-11-10 | Malik Mohammad Tariq | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents |
JP6875683B2 (ja) | 2015-05-19 | 2021-05-26 | 国立研究開発法人国立精神・神経医療研究センター | 多発性硬化症(ms)患者の新規治療適用判断方法 |
EP3398965A4 (en) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
US20200369774A1 (en) | 2017-09-13 | 2020-11-26 | Jiangsu Hengrui Medicine Co., Ltd. | Il-6r antibody and antigen binding fragment thereof and medical use |
US11692037B2 (en) | 2017-10-20 | 2023-07-04 | Hyogo College Of Medicine | Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion |
WO2019177543A1 (en) | 2018-03-15 | 2019-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5216128A (en) | 1989-06-01 | 1993-06-01 | Yeda Research And Development Co., Ltd. | IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it |
RU2139351C1 (ru) | 1991-04-25 | 1999-10-10 | Чугаи Сейяку Кабусики Кайся | Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности |
FR2694767B1 (fr) | 1992-08-13 | 1994-10-21 | Innotherapie Lab Sa | Anticorps monoclonaux anti-IL6R, et leurs applications. |
US5888510A (en) * | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
WO1995009873A1 (en) | 1993-10-06 | 1995-04-13 | Board Of Regents, The University Of Texas System | A monoclonal anti-human il-6 receptor antibody |
IT1274350B (it) | 1994-12-06 | 1997-07-17 | Angeletti P Ist Richerche Bio | Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130 |
IT1274782B (it) | 1994-12-14 | 1997-07-24 | Angeletti P Ist Richerche Bio | Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130 |
JPH08311098A (ja) * | 1995-05-22 | 1996-11-26 | Daicel Chem Ind Ltd | 新規ペプチド類およびそれを含有するインターロイキン6拮抗剤 |
ATE547119T1 (de) * | 1997-03-21 | 2012-03-15 | Chugai Pharmaceutical Co Ltd | Präventives oder therapeutisches mittel mit einem il-6-antagonisten als wirkstoff für durch sensibilisierte t-zellen vermittelte erkrankungen |
DE19923961A1 (de) * | 1999-05-25 | 2000-11-30 | Euro Nippon Kayaku Gmbh | Verwendung von 15-Deoxyspergualin zur Behandlung von hyperreaktiven entzündlichen Erkrankungen und Autoimmunerkrankungen |
JP2003026699A (ja) * | 2001-07-13 | 2003-01-29 | Inter Cyto Nano Science Co Ltd | Il−6シグナル伝達拮抗ペプチド |
CN100374457C (zh) * | 2001-11-14 | 2008-03-12 | 森托科尔公司 | 抗il-6抗体、组合物、方法和用途 |
FR2833011B1 (fr) * | 2001-12-04 | 2004-10-29 | Univ Claude Bernard Lyon | Nouvelle proteine a activite inhibitrice de l'il-6 |
GB2401040A (en) * | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
-
2004
- 2004-12-13 AR ARP040104641A patent/AR048210A1/es unknown
- 2004-12-16 TW TW093139137A patent/TWI351967B/zh active
- 2004-12-17 JP JP2005516531A patent/JP4785534B2/ja active Active
- 2004-12-17 NZ NZ547645A patent/NZ547645A/en unknown
- 2004-12-17 BR BRPI0417072A patent/BRPI0417072B8/pt active IP Right Grant
- 2004-12-17 DK DK04807818.2T patent/DK1707215T3/da active
- 2004-12-17 CN CN2004800378876A patent/CN1893979B/zh active Active
- 2004-12-17 MY MYPI20045223A patent/MY142986A/en unknown
- 2004-12-17 RU RU2006126092/15A patent/RU2379054C2/ru active
- 2004-12-17 ES ES04807818T patent/ES2382809T3/es active Active
- 2004-12-17 WO PCT/JP2004/019463 patent/WO2005061000A1/ja active Application Filing
- 2004-12-17 AT AT04807818T patent/ATE549034T1/de active
- 2004-12-17 EP EP04807818A patent/EP1707215B1/en not_active Revoked
- 2004-12-17 AU AU2004305379A patent/AU2004305379B2/en active Active
- 2004-12-17 CA CA2549467A patent/CA2549467C/en active Active
-
2006
- 2006-06-05 IL IL176122A patent/IL176122A/en active IP Right Grant
- 2006-06-07 ZA ZA200604655A patent/ZA200604655B/en unknown
- 2006-06-12 NO NO20062718A patent/NO20062718L/no not_active Application Discontinuation
- 2006-06-15 KR KR1020067011829A patent/KR101218532B1/ko active IP Right Grant
- 2006-07-14 CO CO06069184A patent/CO5700792A2/es not_active Application Discontinuation
-
2007
- 2007-03-20 HK HK07102960.5A patent/HK1095751A1/xx unknown
-
2013
- 2013-11-22 US US14/087,168 patent/US20140079695A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1707215A4 (en) | 2009-07-15 |
EP1707215A1 (en) | 2006-10-04 |
CA2549467C (en) | 2012-12-11 |
HK1095751A1 (en) | 2007-05-18 |
AR048210A1 (es) | 2006-04-12 |
ATE549034T1 (de) | 2012-03-15 |
AU2004305379B2 (en) | 2011-04-07 |
JPWO2005061000A1 (ja) | 2007-07-12 |
AU2004305379A1 (en) | 2005-07-07 |
IL176122A0 (en) | 2006-10-05 |
DK1707215T3 (da) | 2012-04-16 |
CN1893979B (zh) | 2011-06-08 |
ZA200604655B (en) | 2007-11-28 |
RU2006126092A (ru) | 2008-01-27 |
NZ547645A (en) | 2009-05-31 |
EP1707215B1 (en) | 2012-03-14 |
IL176122A (en) | 2011-07-31 |
KR101218532B1 (ko) | 2013-01-03 |
MY142986A (en) | 2011-02-14 |
KR20060132616A (ko) | 2006-12-21 |
RU2379054C2 (ru) | 2010-01-20 |
ES2382809T3 (es) | 2012-06-13 |
BRPI0417072B1 (pt) | 2017-10-24 |
CN1893979A (zh) | 2007-01-10 |
NO20062718L (no) | 2006-09-18 |
JP4785534B2 (ja) | 2011-10-05 |
WO2005061000A1 (ja) | 2005-07-07 |
BRPI0417072B8 (pt) | 2021-05-25 |
TW200524630A (en) | 2005-08-01 |
CA2549467A1 (en) | 2005-07-07 |
US20140079695A1 (en) | 2014-03-20 |
BRPI0417072A (pt) | 2007-03-13 |
TWI351967B (en) | 2011-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5700792A2 (es) | Un agente preventivo para la vasculitis | |
MX2020011562A (es) | Agonistas del receptor de la hormona tiroidea y usos de los mismos. | |
BR112021022497A2 (pt) | Composto, composição farmacêutica, uso da composição farmacêutica, e, métodos para prevenir ou tratar obesidade, diabetes, inflamação e disfunção erétil | |
BRPI0415505A (pt) | agente terapêutico para mesotelioma | |
ECSP034772A (es) | Antagonistas de mch y su uso en el tratamiento de obesidad | |
ECSP077421A (es) | Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1 | |
ATE530577T1 (de) | Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren | |
EA201390941A1 (ru) | Аналоги глюкагона, проявляющие активность на рецепторе gip | |
NZ756749A (en) | Methods and compositions comprising purified recombinant polypeptides | |
TW200605907A (en) | Preventing autoimmune disease | |
CL2007001665A1 (es) | Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria. | |
PE20120668A1 (es) | Un compuesto n,n-dimetil-5-(2-metil-6-((5-metilpirazin-2-il)carbamoil)benzofuran-4-iloxi)pirimidin-carboxamida como activador de glucocinasa | |
IS2902B (is) | Notkun á CGRP mótlyfsefnasamböndum fyrir meðhöndlun á sóra | |
WO2008002933A3 (en) | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof | |
CO5670356A2 (es) | Programa de dosificaicon para un nuevo agente anticanceroso | |
SV2006002342A (es) | Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida | |
BRPI0510617A (pt) | uso de expressão de il-17 para prever inflamação de pele; processos de tratamento | |
BRPI0409910A (pt) | métodos para o tratamento de doenças relacionadas com interleucina-6 | |
NO20080487L (no) | Rekominant interferona2 (IFNa2) mutanter | |
RU2019143573A (ru) | Комбинированная терапия нейропсихиатрических расстройств, восприимчивых к антагонисту nmdar | |
DE602005024959D1 (de) | Pharmazeutische zusammensetzung mit einer salbe und zwei aufgelösten wirkstoffen | |
PH12019501900A1 (en) | Treatment of hidradenitis suppurativa | |
PE20081547A1 (es) | Agentes terapeuticos que contienen un antagonista de interleucina-6 como ingrediente activo | |
CO2022013055A2 (es) | Tafoxiparina para el tratamiento de la preeclampsia | |
AR044452A1 (es) | Combinacion de un antagonista del receptor p2x7 y un inhibidor del factor de necrosis tumoral alfa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |